Serna Bio - Lecture Series #2
The Serna Bio lecture series will spotlight bold, creative operators and founders working across the spectrum of AI and biology, showcasing the many different paths shaping the future of this rapidly evolving field.
This lecture features Andrew Goldberg who is responsible for the day-to-day operations and performance excellence of HealthVerity. Andrew has helped to build HealthVerity into the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data at scale. He was formerly the SVP Strategy and Marketing for Dialogic and the VP Corporate Development for Avaya which was sold to Silverlake/TPG. He currently serves on the Board of Directors of Philadelphia Ballet and the Hassel Foundation. Andrew holds an MBA with Distinction from Harvard Business School and a BA with Honors from the University of Pennsylvania.
The Serna Bio Discovery Platform integrates target discovery, generative chemical design, and in-cell screening to identify and optimize selective RNA-binding molecules.
Our foundation includes:
* The world’s largest atlas of experimentally validated RNA structures
* A generative chemistry engine that outperforms state-of-the-art methods such as NVIDIA MolMIMM.
This technology has enabled the creation of an entirely new class of small molecules—translational enhancers—that modulate RNA to restore or increase protein expression, offering novel therapeutic paths in neurodegeneration and cardiometabolic disease.